[35] K. Kariko, et al., “Incorporation of pseudouridine into mRNA yields superior
nonimmunogenic vector with increased translational capacity and biological stabi-
lity,” Mol. Ther., vol. 16, no. 11, p. 1833–1840, 2008.
[36] CB, R., et al., “Manufacturing considerations for the development of lipid nano-
particles using microfluidics,” Pharmaceutics, vol. 12, 1–19, 2020.
[37] KJ, H., et al. “Optimization of lipid nanoparticles for intramuscular administration
of mRNA vaccines,” Mol. Ther. Nucleic Acids, vol. 15, 1–11, 2019.
[38] AM, R., MA, O., A, J., R, L. & D, B. “mRNA vaccine delivery using lipid nano-
particles,” Ther. Deliv., vol. 7, pp. 319–334, 2016.
[39] M. S. Ali, N. Hooshmand, M. El-Sayed & H. I. Labouta “Microfluidics for de-
velopment of lipid nanoparticles: Paving the way for nucleic acids to the clinic,”
ACS Appl. Bio Mater., 2021. doi: 10.1021/ACSABM.1C00732.
[40] Committee for Medicinal Products for Human Use (CHMP), E.M.A., “Assessment
report, COVID-19 Vaccine Moderna, Common name: COVID-19 mRNA Vaccine
(nucleoside-modified), Procedure No. EMEA/H/C/005791/0000,” E.M. Agency,
Editor, p. 169, 2021.
[41] L. R. Baden, et al., “Efficacy and safety of the mRNA-1273 SARS-CoV-2
Vaccine,” N. Engl. J. Med., vol. 384, no. 5, pp. 403–416, 2021.
[42] P. H. Kremsner, et al., “Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA
vaccine candidate in ten countries in Europe and Latin America (HERALD): A
randomised, observer-blinded, placebo-controlled, phase 2b/3 trial,” Lancet Infect.
Dis., vol. 22, no. 3, pp. 329–340, 2022.
[43] P. L. Stern, “Key steps in vaccine development,” Ann. Allergy Asthma Immunol.,
vol. 125, no. 1, pp. 17–27, 2020.
[44] F. C. Zhu, et al., “Immunogenicity and safety of a recombinant adenovirus type-5-
vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised,
double-blind, placebo-controlled, phase 2 trial,” Lancet, vol. 396, no. 10249,
pp. 479–488, 2020.
[45] T. Ura, K. Okuda, and M. Shimada, “Developments in viral vector-based vaccines,”
Vaccines (Basel), vol. 2, no. 3, pp. 624–641, 2014.
[46] G. L. Smith, M. Mackett, and B. Moss, “Infectious vaccinia virus recombinants that
express hepatitis B virus surface antigen,” Nature, vol. 302, no. 5908, pp. 490–495,
1983.
[47] S. M. Vrba, et al., “Development and applications of viral vectored vaccines to
combat zoonotic and emerging public health threats,” Vaccines (Basel), vol. 8,
no. 4, 680, 2020. https://doi.org/10.3390/vaccines8040680
[48] Committee for Medicinal Products for Human Use (CHMP), E.M.A., “Assessment
report, COVID-19 Vaccine AstraZeneca, Common name: COVID-19 Vaccine
(ChAdOx1-S [recombinant]), Procedure No. EMEA/H/C/005675/0000”, E.M.
Agency, Editor. p. 181, 2021.
[49] Z. Chagla, “In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against
COVID-19 >14 d after the 2nd dose,” Ann. Intern. Med., vol. 174, no. 3, p. JC29, 2021.
[50] M. Voysey, et al., “Safety and efficacy of the ChAdOx1 nCoV-19 vaccine
(AZD1222) against SARS-CoV-2: an interim analysis of four randomised con-
trolled trials in Brazil, South Africa, and the UK,” Lancet, vol. 397, no. 10269,
p. 99–111, 2021.
[51] N. H. Schultz, et al., “Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19
vaccination,” N. Engl. J. Med., vol. 384, no. 22, pp. 2124–2130, 2021.
[52] E. H. Livingston, P. N. Malani, and C. B. Creech, “The Johnson & Johnson vaccine
for COVID-19,” JAMA, vol. 325, no. 15, p. 1575, 2021.
[53] J. Sadoff, et al., “Safety and efficacy of single-dose Ad26.COV2.S vaccine against
Covid-19,” N. Engl. J. Med., vol. 384, no. 23, pp. 2187–2201, 2021.
COVID-19 vaccines
313